KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Retained Earnings: 2018-2025

Historic Retained Earnings for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$1.7 billion.

  • Esperion Therapeutics' Retained Earnings fell 6.70% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 6.70%. This contributed to the annual value of -$1.6 billion for FY2024, which is 3.34% down from last year.
  • Esperion Therapeutics' Retained Earnings amounted to -$1.7 billion in Q3 2025, which was down 1.89% from -$1.7 billion recorded in Q2 2025.
  • Esperion Therapeutics' Retained Earnings' 5-year high stood at -$928.2 million during Q1 2021, with a 5-year trough of -$1.7 billion in Q3 2025.
  • For the 3-year period, Esperion Therapeutics' Retained Earnings averaged around -$1.6 billion, with its median value being -$1.6 billion (2024).
  • Data for Esperion Therapeutics' Retained Earnings shows a maximum YoY tumbled of 49.77% (in 2021) over the last 5 years.
  • Over the past 5 years, Esperion Therapeutics' Retained Earnings (Quarterly) stood at -$1.1 billion in 2021, then declined by 21.12% to -$1.3 billion in 2022, then dropped by 15.62% to -$1.5 billion in 2023, then decreased by 3.34% to -$1.6 billion in 2024, then dropped by 6.70% to -$1.7 billion in 2025.
  • Its last three reported values are -$1.7 billion in Q3 2025, -$1.7 billion for Q2 2025, and -$1.6 billion during Q1 2025.